porozendoОстеопороз и остеопатииOsteoporosis and Bone Diseases2072-26802311-0716Endocrinology Research Centre10.14341/osteo2013135-38porozendo-8847Research ArticleСтатьиArticlesЭФФЕКТ БЕТА-АДРЕНОБЛОКАТОРОВ НА МИНЕРАЛЬНУЮ ПЛОТНОСТЬ КОСТИ И ОСТЕОПОРОТИЧЕСКИЕ ПЕРЕЛОМЫ. ОБЗОР ЛИТЕРАТУРЫEFFECT OF BETA-BLOCKERS ON BONE MINERAL DENSITY AND OSTEOPOROTIC FRACTURESСобченкоК ЕSobchenkoK E
аспирант отдела профилактики остеопороза
KSobchenko@gnicpm.ruСкрипниковаИ АSkripnikovaI A
руководитель отдела профилактики остеопороза
-АбироваЭ СAbirovaE S
старший научный сотрудник отдела профилактики остеопороза
-ПтичкинаП АPtichkinaP A
научный сотрудник отдела профилактики остеопороза
-ФГБУ «Государственный научно-исследовательский центр профилактической медицины» Минздрава России201315122013161№1 (2013)3538Copyright © Собченко К.Е., Скрипникова И.А., Абирова Э.С., Птичкина П.А., 20132013Собченко К.Е., Скрипникова И.А., Абирова Э.С., Птичкина П.А.Sobchenko K.E., Skripnikova I.A., Abirova E.S., Ptichkina P.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.osteo-endojournals.ru/jour/article/view/8847
В обзоре представлены современные данные о плейотропных эффектах бета-адреноблокаторов, в частности, о влиянии на костную массу и развитие переломов на фоне хрупкости костной ткани. Обсуждаются механизмы действия бета-адреноблокаторов на костный метаболизм и возможности их протективного эффекта на костную ткань в комплексной терапии ССЗ.
This review presents the current data on the pleiotropic effects of beta-blockers in particular on the effect on bone mass and fracture development by means of increased bone fragility. In this article we discuss the mechanisms of action of beta-blockers on bone metabolism and their possible protective effect on bone tissue in the treatment of cardiovascular disease.
ЭФФЕКТ БЕТА-АДРЕНОБЛОКАТОРОВ НА МИНЕРАЛЬНУЮ ПЛОТНОСТЬ КОСТИ И ОСТЕОПОРОТИЧЕСКИЕ ПЕРЕЛОМЫ. ОБЗОР ЛИТЕРАТУРЫ
ReferencesBrowner W.S., Seeley D.G., Vogt T.V. Non-trauma mortality in elderly women with low bone mineral density. Study of Osteoporotic Fractures Research Group. Lancet 1991; 338: 335-38.Browner W.S., Seeley D.G., Vogt T.V. Non-trauma mortality in elderly women with low bone mineral density. Study of Osteoporotic Fractures Research Group. Lancet 1991; 338: 335-38.Tanko L.B., Christiansen C., Cox D.A., et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 2005; 20: 1912-1920.Tanko L.B., Christiansen C., Cox D.A., et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 2005; 20: 1912-1920.Magnus J.H., Broussard D.L., Relationship between BMD and myocardial infarction in US adults. Osteoporos Int 2005; 16: 2053-2062.Magnus J.H., Broussard D.L., Relationship between BMD and myocardial infarction in US adults. Osteoporos Int 2005; 16: 2053-2062.Perez-Castrillon J.L., Abad L., Vega G., et al. Bone mineral density, bone remodeling and osteoprotegerin in patients with acute coronary syndrome. Int JCardiol 2008; 129: 144-145.Perez-Castrillon J.L., Abad L., Vega G., et al. Bone mineral density, bone remodeling and osteoprotegerin in patients with acute coronary syndrome. Int JCardiol 2008; 129: 144-145.Kenni A.M., Boxer R., Walsh S., et al. Femoral BMD in patients with heart failure. Osteoporos Int. 2006; 17: 1420-1427.Kenni A.M., Boxer R., Walsh S., et al. Femoral BMD in patients with heart failure. Osteoporos Int. 2006; 17: 1420-1427.von der Recke P., Hanse M.A., Hassanger C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 1999; 106:273-278.von der Recke P., Hanse M.A., Hassanger C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 1999; 106:273-278.Bartholow M. Top 200 prescription drugs of 2009, Pharmacy Times 2010.Bartholow M. Top 200 prescription drugs of 2009, Pharmacy Times 2010.Moore R.E., Smith C.K., Bailey C.S. et.al. Characterisation of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can simulate bone resorption in organ culture. J Bone Miner Res 1993; 23:301-15.Moore R.E., Smith C.K., Bailey C.S. et.al. Characterisation of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can simulate bone resorption in organ culture. J Bone Miner Res 1993; 23:301-15.Takeda S., Elefteriou F., Levasseur R., et. al. Leptin inhibits bone formation via the sympathetic nervous system. Cell 2002; 189: 47-60.Takeda S., Elefteriou F., Levasseur R., et. al. Leptin inhibits bone formation via the sympathetic nervous system. Cell 2002; 189: 47-60.Ducy P., Amling M., Takeda S. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000; 100: 197-207.Ducy P., Amling M., Takeda S. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000; 100: 197-207.Majeska R.J., Minkowitz B., Bastian W., Einhorn T.A. Effects of beta-adrenergic blockade in an osteoblast-like cell line. J Orthop Res 1992; 10: 370-84.Majeska R.J., Minkowitz B., Bastian W., Einhorn T.A. Effects of beta-adrenergic blockade in an osteoblast-like cell line. J Orthop Res 1992; 10: 370-84.Pasco J.A., Henry M.J., Nicholson G.C., et.al. B-blockers reduce bone resorption marker in early postmenopausal women. Ann Human Biol. 2005; 32: 738-745Pasco J.A., Henry M.J., Nicholson G.C., et.al. B-blockers reduce bone resorption marker in early postmenopausal women. Ann Human Biol. 2005; 32: 738-745Reid I.R., Lucas J., Wattie D., et al. Effects of a beta-blocker on bone turnover in normal postmenopausal women. Randomized controlled trial. J Clin Endocrinol Metab 2005; 90: 5212-16.Reid I.R., Lucas J., Wattie D., et al. Effects of a beta-blocker on bone turnover in normal postmenopausal women. Randomized controlled trial. J Clin Endocrinol Metab 2005; 90: 5212-16.Rejnmark L., Vestergaard P., Kassem M., et.al. Fracture risk in perimenopausal women treated with beta-blockers. Calcif Tissue Int 2004; 75: 365-372.Rejnmark L., Vestergaard P., Kassem M., et.al. Fracture risk in perimenopausal women treated with beta-blockers. Calcif Tissue Int 2004; 75: 365-372.Pasco J.A., Henry M.J., Sanders K.M., et.al. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res 2004; 19: 19-24.Pasco J.A., Henry M.J., Sanders K.M., et.al. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res 2004; 19: 19-24.Schoofs M., Sturkenboom P.,Van Leeuwen J., et.al. Use of beta-blockers is associated with BMD and fracture risk. Bone 2005; 36 S2: 129-130.Schoofs M., Sturkenboom P.,Van Leeuwen J., et.al. Use of beta-blockers is associated with BMD and fracture risk. Bone 2005; 36 S2: 129-130.Bonnet N., Gadois C., McCloskey E., et.al. Protective effect of beta-blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture. Bone 2007; 40: 1209-1216.Bonnet N., Gadois C., McCloskey E., et.al. Protective effect of beta-blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture. Bone 2007; 40: 1209-1216.Reid I.R, Gamble G.D., Grey A.B, et al. Beta-blockers use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 2005; 20:613-8Reid I.R, Gamble G.D., Grey A.B, et al. Beta-blockers use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 2005; 20:613-8Lavasseur R., Marcelli C., Savatier J.p. et al. Beta-blockers use, BMD, and fractures risk in older women: results from the Epidemiologie de L’Osteoporose Prospective Study. J Am Geriatr Soc 2005; 53: 550-552.Lavasseur R., Marcelli C., Savatier J.p. et al. Beta-blockers use, BMD, and fractures risk in older women: results from the Epidemiologie de L’Osteoporose Prospective Study. J Am Geriatr Soc 2005; 53: 550-552.Yang S., Nguyen N.D., Center J.R., et.al. Association between beta-blockers use and fracture risk: the Dubbo Osteoporosis Epidemiology Study. Bone 2011; 48(3): 451-455.Yang S., Nguyen N.D., Center J.R., et.al. Association between beta-blockers use and fracture risk: the Dubbo Osteoporosis Epidemiology Study. Bone 2011; 48(3): 451-455.Turker S., Karatosun V., Gunai I. Beta-blockers increase bone mineral density. Clin Orthop 2006; 443: 73-74.Turker S., Karatosun V., Gunai I. Beta-blockers increase bone mineral density. Clin Orthop 2006; 443: 73-74.Schlienger R.G., Kraenzlin M.E., Jick S.S., Meier C.R. Use of beta-blockers and risk of fractures. JAMA 2004; 292: 1326-32.Schlienger R.G., Kraenzlin M.E., Jick S.S., Meier C.R. Use of beta-blockers and risk of fractures. JAMA 2004; 292: 1326-32.de Vries F., Souverein P.C., Leufkens H.G., van Staa T.P. Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and the Netherlands. Calcif Tissue Int 2007; 80: 69-75.de Vries F., Souverein P.C., Leufkens H.G., van Staa T.P. Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and the Netherlands. Calcif Tissue Int 2007; 80: 69-75.Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 2006; 24: 581-9.Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 2006; 24: 581-9.Weins M., Etminan M., Gill S.S., Takkouche B., Effects of antihypertensive drug treatments on fractures outcomes: a meta-analysis of observational studies. Journal of international studies 2006; 260: 350-62.Weins M., Etminan M., Gill S.S., Takkouche B., Effects of antihypertensive drug treatments on fractures outcomes: a meta-analysis of observational studies. Journal of international studies 2006; 260: 350-62.Meisinger C., Heier M., Lang O., Doring A. Beta-Blocker use and risk of fractures in men and women from the general population: the MONICA/KORA Ausburg cohort study. Osteoporos Int 2007; 18(9): 1189-95.Meisinger C., Heier M., Lang O., Doring A. Beta-Blocker use and risk of fractures in men and women from the general population: the MONICA/KORA Ausburg cohort study. Osteoporos Int 2007; 18(9): 1189-95.Reid I.R., Gamble G.D., Grey A.B. et.al. Beta-blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 2005; 20: 613-8.Reid I.R., Gamble G.D., Grey A.B. et.al. Beta-blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 2005; 20: 613-8.Butt D.A., Mamdani M., Austin PC. et.al. The risk of hip fracture after initiating antihypertensive drugs in the eldery. Arch Intern Med 2012; 172(22): 1739-44.Butt D.A., Mamdani M., Austin PC. et.al. The risk of hip fracture after initiating antihypertensive drugs in the eldery. Arch Intern Med 2012; 172(22): 1739-44.Toker. A, Gulcan E., Toker S., et.al. Nebivolol might be beneficial in osteoporosis treatment: a hypothesis. TJPR 2009; 8(2): 181-186.Toker. A, Gulcan E., Toker S., et.al. Nebivolol might be beneficial in osteoporosis treatment: a hypothesis. TJPR 2009; 8(2): 181-186.Гудырев О.С. Остеопротективное действие эналаприла и лазартана при эксперементальном остеопорозе и переломах на его фоне. Автореферат 2009.Гудырев О.С. Остеопротективное действие эналаприла и лазартана при эксперементальном остеопорозе и переломах на его фоне. Автореферат 2009.
The authors declare that there are no conflicts of interest present.